Cost-effectiveness of nivolumab for recurrent or metastatic head and neck cancer☆

Head and neck cancer (HNC) is common and its frequency is increasing, with over 61,000 cases in the United States per year [1–3]. After definitive treatment, approximately 30–40% will progress [4–6]. Platinum-based systemic chemotherapy is the first treatment for patients with incurable recurrent or metastatic disease. Until recently, no agent has demonstrated efficacy following progression after standard platinum-based regimens, with most data suggesting a median survival of 5–6months regardless of regimen [7–9].

http://ift.tt/2A2o8Zg